EyePoint (EYPT) Deferred Taxes (2011 - 2025)
EyePoint (EYPT) reported Deferred Taxes of $369000.0 for Q4 2025, up 310.0% on a YoY basis from $90000.0 in Q4 2024, and up 310.0% sequentially from $90000.0 in Q4 2024.
EyePoint (EYPT) Deferred Taxes (2011 - 2025) Analysis & Trends
EyePoint (EYPT) has 3 years of Deferred Taxes data on file, last reported at $369000.0 in Q4 2025.
- For the quarter ending Q4 2025, Deferred Taxes rose 310.0% year-over-year to $369000.0; the trailing twelve-month figure through Dec 2025 stood at $459000.0 (up 410.0% YoY), and the FY2025 full-year result was $279000.0, up 210.0% from the prior year.
- Deferred Taxes grew to $369000.0 in Q4 2025, from $90000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $369000.0 in Q4 2025 to a low of $90000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2011 | -13,000.00 |
| Jun 30, 2011 | -119,000.00 |